USA – Microspheres for knee osteoarthritis get breakthrough status

Varian announced today that it received FDA breakthrough device designation for its Embozene microspheres for treating knee osteoarthritis.

Palo Alto, California-based Varian, a Siemens Healthineers (ETR:SHL) company, designed Embozene for genicular artery embolization (GAE) in treating symptomatic knee osteoarthritis. Embozene already holds FDA clearance for the embolization of hypervascular tumors, arteriovenous malformations, uterine fibroids and benign prostatic hyperplasia…